lane
Veteran
I guess time will tell. Don't think there's merit in slowing down the vaccination programme, giving it gives evidence-based protection from serious illness and death, and putative reduction in transmission: and therefore overall numbers infected. In South Africa the proportion of variants is substantially different to UK so their decision to pause the use of the Oxford-AZ vaccine because of this small cohort inefficacy result is based on different circumstances. I note that the Pfizer vaccine has not been tested (clinical trial) against the B.1.351 variant, sfaik. Maybe it will do better.
Recommend two snips of media to people: Oxford Uni's Prof Sarah Gilbert's interview on the 'Andrew Marr show' on Sat am (about 0940 - 32:50 - 46:00) and a set of Q&A with two experts (one ex-RCGP Head, one JCVI) on BBC's 'Today' programme this Tue am (0842-0855 2:41:50 - 2:55:00). One of the questions in the latter makes exactly @roubaixtuesday 's point (above, about the effect of the vaccine suppressing the B.1.1.7 variant and therefore giving benefit to the B.1.351 variant). Answer (my best): "There'll be lots of variants; think the focus is too much on the SA variant; yes, vaccination will have effect on relative variant success but it's still the way out of high levels of serious illness and deaths; it's a paradox."
I agree there is no merit in slowing down the programme. However where is the evidence based protection from serious illness and death, from what I gather it is at best inferred for the AZ vaccine.
Flu of course changes every year but the world has a well established approach for dealing with that. Covid still seems very much an unknown in terms of how it will mutate and how often.